Holen Sie sich die Stockscreener-App
1.0181
3.27%
0.0322
In 8 Bio Inc Aktie (INAB) Neueste Nachrichten
IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire Inc.
A new hire’s right to buy IN8bio shares begins after one year. - Stock Titan
IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Daily Tribune News
IN8bio (INAB) Stock Analysis: Climbs +9.02%, Eyes on $1.52 2026-10-01Volume Spike Alerts - https://www.siam.in/
IN8bio (INAB) Stock Analysis: Climbs +9.02%, Eyes on $1.52 2026-10-01Leveraged ETF Flow - https://www.dars.gov.et/
IN8bio to Present at Sidoti Small-Cap Virtual Conference - GlobeNewswire Inc.
Kala Bio Secures 5-Year Exclusive U.S. Distribution for Ophthalmic Genetic Testing With Virotek - tradingview.com
IN8bio CEO William Ho will speak at a Sept. 14 investor conference - Stock Titan
KALA BIO (NASDAQ: KALA) sets Sept. 19 cutoff for 2026 shareholder proposals - Stock Titan
A drug developer with 20 years’ experience joins IN8bio - Stock Titan
Braveheart Bio Completes IPO with $122.8 Million in Gross Proceeds - Minichart
Adicet Bio posts September 2026 investor presentation outlining prula-cel and ADI-212 clinical timelines - TradingView
Braveheart Bio (NASDAQ:BRVE) Trading Up 8%Should You Buy? - MarketBeat
PeproMene Bio Announces Publication in The Lancet of Breakthrough Phase 1 Clinical Trial Results Demonstrating Deep and Durable Complete Responses in Relapsed/Refractory B-cell Lymphomas, including after prior CD19 CAR T-cell failure - BioSpace
GRI Bio posts Phase 2a IPF biomarker and safety data; +99 mL placebo‑adj FVC, supports longer study - TradingView
Experimental IPF pill from GRI Bio (GRI) boosts lung function in 12 weeks as company eyes 52-week study - stocktitan.net
Cough during treatment was 0% with GRI Bio's drug, versus 25% on placebo - stocktitan.net
PeproMene Bio Announces Publication in The Lancet of Breakthrough Phase 1 Clinical Trial Results Demonstrating Deep and Durable Complete Responses in Relapsed/Refractory B-cell Lymphomas, including after prior CD19 CAR T-cell failure - Morningstar
symbol__ Stock Quote Price and Forecast - CNN
Investor group in Valion Bio (VBIO) shifts to passive stake - Stock Titan
[425] Passage BIO, Inc. Business Combination Communication | PASG SEC FilingForm 425 - Stock Titan
Valion Bio Raises $7.74 Million Via Series B/C Preferred and Warrants From 3i - TradingView
2,426,857 Boundless Bio (NASDAQ: BOLD) shares held by Zachary Hornby - Stock Titan
KALA BIO Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Gossamer Bio (NASDAQ: GOSS) ties CFO’s 5.8M options to seralutinib FDA decision - Stock Titan
Valion Bio, Inc. SEC Filing (Aug 24, 2026) - Stock Titan
Gossamer Bio (NASDAQ: GOSS) has 6% of its stock under D. E. Shaw’s reported influence - Stock Titan
abrdn (AWP) Latest: Retreats 0.34% to $11.80 in the Latest Session; Chart Watch: $11.21 and $12.39 Define the Nearby Reference Levels in the Current UpdateIV Percentile - dars.gov.et
TBIO | TELESIS BIO INC Insider Trading - Quiver Quantitative
IN8bio (INAB): Posts a 5.79% Gain to $1.28 in the Latest Reading; Level Watch: Price Remains Between $1.22 Support and $1.34 Resistance in Latest TradingPut Flow Alert - https://www.dars.gov.et/
Gossamer Bio Lines Up Up To $250 Million Private Placement With Milestone-Triggered Warrants - TradingView
3i injects cash into Valion Bio (VBIO) under tight ownership cap - Stock Titan
IN8bio (INAB) Q2 2026 Results: EPS Clears the Reported Estimate in the Latest Session; Post-Earnings: The Stock Gains 5.26% on the DayAnnual Financial Report - https://www.dars.gov.et/
Tech workers may be better off selling their company stock - Business Insider
TELA Bio (TELA) stake: Nantahala group reports 12.94% ownership of 5.79M shares - Stock Titan
Palisade Bio (PALI): Commodore Capital group now reports 0.0% beneficial ownership - Stock Titan
Climb Bio, Inc. (CLYM): MPM BioImpact LLC reports 0% ownership in amendment - Stock Titan
Point72 discloses 4.95% Q32 Bio Inc. (QTTB) holding in Schedule 13G/A - Stock Titan
Cormorant Asset Management (CABA) discloses 10M-share Cabaletta Bio stake - Stock Titan
Highbridge Capital (ANVS) discloses 6.1% Annovis Bio stake tied to 2.78M warrant shares - Stock Titan
Cabaletta Bio (CABA): T. Rowe Price reports 11.6% common stock stake - Stock Titan
Q32 Bio Inc. (QTTB) major holders cut reported stake to 0% - Stock Titan
Caballeta Bio (CABA) stake: Bain Capital Life Sciences reports 9.99% position - Stock Titan
Korro Bio (KRRO) director-affiliated funds sell 2,143 shares under 10b5-1 plan - Stock Titan
Instil Bio (Nasdaq: TIL) trims Q2 2026 loss and extends cash runway - Stock Titan
BIO-key International (BKYI) secures $2.51M and issues 1.24M new warrants in financing - Stock Titan
Palisade Bio (PALI): Soleus group reports 7.5% stake, 13.1M shares held - Stock Titan
Cabaletta Bio (CABA) lifts cash to $225M while advancing rese-cel toward BLA - Stock Titan
5.07%
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):